Shon Green
Co-Founder Zelig Tx
Seminars
Thursday 17th September 2026
Q-CAR: An In Vivo CAR-T Targeting IgE B-Cells as a Treatment for Severe Allergies
3:20 pm
- Developing a novel in vivo CAR-T approach as a potential cure for severe allergic diseases
- Highlighting the technology, regulatory, and CMC developments that make it possible to envision an in vivo CAR-T product for allergy
- Demonstrating preclinical proof of concept, de-risking translation, and defining a successful clinical strategy to advance in vivo Q-CAR in allergy
